{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Black Diamond Therapeutics, Inc.
Is Black Diamond Therapeutics, Inc. overvalued or undervalued?
As of October 17, 2025, Black Diamond Therapeutics, Inc. is considered attractive but overvalued with a P/E ratio of 29 compared to the sector average of 12.03, despite a strong year-to-date return of 87.38% that contrasts with its negative long-term performance.
Black Diamond Therapeutics Experiences Valuation Adjustment Amid Strong Market Performance
Black Diamond Therapeutics, Inc. has recently adjusted its valuation, showcasing a P/E ratio of 29 and a price-to-book value of 1.04. The company reports strong financial metrics, including a 55.79% ROCE and a PEG ratio of 0.27, indicating a favorable position compared to peers facing financial challenges.
Is Black Diamond Therapeutics, Inc. overvalued or undervalued?
As of October 17, 2025, Black Diamond Therapeutics, Inc. is considered overvalued with a high P/E ratio of 29 compared to the peer average of 12.03, despite a favorable PEG ratio of 0.27, indicating a shift in valuation from very attractive to attractive.
Is Black Diamond Therapeutics, Inc. overvalued or undervalued?
As of October 17, 2025, Black Diamond Therapeutics, Inc. is considered attractive but overvalued with a P/E ratio of 29 compared to the peer average of 12.03, despite a strong year-to-date return of 87.38%, raising concerns about its long-term sustainability after an 88.10% decline over the past five years.
Black Diamond Therapeutics Hits New 52-Week High of $4.11
Black Diamond Therapeutics, Inc. achieved a new 52-week high of USD 4.11 on October 8, 2025, despite a challenging year. The company reported positive results over the last three quarters, with significant operating cash flow and net profit, while maintaining strong institutional investor confidence.
Black Diamond Therapeutics Hits New 52-Week High at $4.03
Black Diamond Therapeutics, Inc. achieved a new 52-week high of USD 4.03 on October 6, 2025, despite a challenging year marked by a 23.29% decline. The company, with a market cap of USD 174 million, has shown positive financial performance, including three consecutive profitable quarters.
Black Diamond Therapeutics Hits New 52-Week High at $3.90
Black Diamond Therapeutics, Inc. achieved a new 52-week high of USD 3.90 on October 3, 2025, despite a challenging year. The company has reported positive results for three consecutive quarters, with significant operating cash flow and net profit, reflecting effective management and strong institutional ownership.
Is Black Diamond Therapeutics, Inc. technically bullish or bearish?
As of September 4, 2025, Black Diamond Therapeutics, Inc. shows a bullish trend with strong indicators, despite some caution from weekly and monthly KST readings, and has a year-to-date return of 56.54%, outperforming the S&P 500's 12.22% return.
Is Black Diamond Therapeutics, Inc. overvalued or undervalued?
As of September 2, 2025, Black Diamond Therapeutics, Inc. is considered overvalued with a P/E ratio of 29, despite a year-to-date return of 56.54%, indicating a shift in valuation from very attractive to attractive and raising concerns about its long-term growth potential compared to peers.
Is Black Diamond Therapeutics, Inc. overvalued or undervalued?
As of May 12, 2025, Black Diamond Therapeutics, Inc. is considered overvalued with a P/E ratio of 29, a PEG ratio of 0.27, and a significant stock decline of 53.10% over the past year, contrasting with the S&P 500's 10.26% return.
Is Black Diamond Therapeutics, Inc. technically bullish or bearish?
As of June 17, 2025, the market trend is neutral with mixed signals, showing mild bullishness on the MACD and Bollinger Bands weekly but bearishness monthly, while moving averages and KST indicate indecision.
Who are in the management team of Black Diamond Therapeutics, Inc.?
As of March 2022, the management team of Black Diamond Therapeutics, Inc. includes Mr. Robert Ingram (Independent Chairman), Dr. David Epstein (CEO), and several directors: Dr. Bradley Bolzon, Dr. Kapil Dhingra, Mr. Alexander Mayweg, Dr. Ali Behbahani, and Dr. Samarth Kulkarni. The team features a mix of independent directors and executives, ensuring diverse leadership.
What does Black Diamond Therapeutics, Inc. do?
Black Diamond Therapeutics, Inc. is a precision oncology medicine company with a market cap of $131.92 million, reporting net sales of $70 million and a net profit of $57 million as of March 2025. Key metrics include a P/E ratio of 29.00 and a return on equity of 3.60%.
How big is Black Diamond Therapeutics, Inc.?
As of Jun 18, Black Diamond Therapeutics, Inc. has a market capitalization of 131.92 million and reported net sales of 70.00 million with a net profit of 5.09 million over the latest four quarters. Shareholder's funds are 83.28 million, and total assets are 122.64 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
